Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the ...

Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and ...

Biotechnology company Leucid Bio announced a strategic collaboration with Syenex, an open-source gene therapy platform firm.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...